Caribou Biosciences, Inc. Overview
Pro stress-test →Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company developing allogeneic CAR-T cell therapies for hematologic malignancies and multiple myeloma. The company is preparing a pivotal phase 3 trial for vispa-cel and expanding CB-011 development, targeting significant commercial opportunities in cell therapy.
Strategic Profile
Pro stress-test →Caribou achieved FDA alignment on the pivotal ANTLER-3 trial design for vispa-cel and secured RMAT designation for CB-011 with strong early response rates (May 2026). With $118.6 million in cash as of March 31, 2026, the company's runway extends through at least 12 months of operations while exploring funding options for the vispa-cel pivotal trial.
Competitive Landscape
Pro stress-test →Caribou competes in the allogeneic CAR-T and CRISPR-based cell therapy space against established players including Juno Therapeutics (Celgene/Bristol Myers Squibb), Autolus Therapeutics, and Precision Biosciences. Competitive advantages include CRISPR-based manufacturing and off-the-shelf cell therapy positioning, though clinical efficacy and regulatory approval timelines will determine market share.
Industry Context
Caribou Biosciences, Inc. operates in Regenerative Medicine.
Key facts
Founded: 2011 · Headquarters: Berkeley, US · Employees: N/A · Revenue: $11.2M (FY2025) · Market cap: N/A